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Abstract: The aim of this study was to evaluate the treatment and
prognosis of gastric gastrointestinal stromal tumors (GISTs) according to
the 7th UICC/AJCC tumor-node-metastasis (TNM) system and the
modifiedNational Institutes of Health (NIH) risk classification. The study
cohort consisted of 1057 patients with gastric GIST who underwent
surgery between January 2000 and December 2007 from 13 institutions
in Korea and 2 in Japan. Clinicopathologic characteristics, surgical out-yu-Seok Cho, MD, im, MD, PhD,
oon-Won Yoo, MD, PhD
Complete resection (R0 resection) was achieved in 1018 patients
(96.3%). Eighty-six patients (8.1%) had postoperative complications,
and 2 patients (0.2%) died within 30 days after surgery. According to the
7th UICC/AJCCTNM system, 5-year recurrence-free survival rates were
95% to 99% in stage I, 94.1% in stage II, 74.1% in stage IIIA, 48.6% in
stage IIIB, and 50.0% in stage IV patients. On survival analysis of high-
risk patients according to the TNM system, the 5-year recurrence-free
survival rates were 91.6% in stage II, 74.1% in stage IIIA, and 48.6% in
stage IIIB patients. Independent factors of recurrence following surgery
for gastric GIST were gender, tumor size, mitotic count, and radicality on
multivariate analysis.
The treatment outcome and prognosis of gastric GIST in Korea and
Japan seem more favorable compared to those in Western countries.
Compared to the modified NIH risk classification, the 7th UICC/AJCC
TNM system is more reflective of the 5-year recurrence-free survival of
patients with gastric GIST.
(Medicine 94(41):e1526)
Abbreviations: AJCC = American Joint Committee on Cancer,
CRF = case report form, GIST = gastrointestinal stromal tumor,
HPF = high power field, NIH = National Institutes of Health, TNM
= tumor-node-metastasis, UICC = Union for International Cancer
Control.
INTRODUCTION
G astrointestinal stromal tumors (GIST) originate from theinterstitial cells of Cajal, intestinal pacemaker cells in the
gastrointestinal tract.1,2 GISTs metastasize mainly to the liver
via hematogenous spread and disseminate throughout the per-
itoneal cavity.3 They are primarily located in the stomach (60–
70%) and are also found in the small intestine (20–30%),
esophagus (5%), and colon and rectum (5%).4 Surgery is a
potentially curative treatment for patients with resectable GIST.
The purpose of surgery for resectable GIST is complete resec-
tion with tumor-free margins, avoiding tumor rupture,5 because
tumor rupture, either spontaneously or at surgery, is associated
with a high risk of recurrence. Whether rupture is an indepen-
dent risk factor remains controversial.6 However, the prognosis
of patients with primary GIST is influenced by tumor size and
its mitotic count.3,4,6 Imatinib mesylate (Glivec1, Novartis,
Basel, Switzerland) was established as the treatment of choiceerable or metastatic disease. A recent
r phase III trial has shown that 3 years of
ves overall survival compared to 1 year
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FIGURE 1. Annual number of patients. The number of patients
Medicine  Volume 94, Number 41, October 2015of therapy.7 Imatinib is also being investigated in the neoadju-
vant setting to downstage unresectable tumors to resectable
stage.8
In 2005, Miettinen et al9 reported on a large retrospective
study of 1765 patients with gastric GISTs who were followed
over the long term. Their study provides extensive information
on gastric GIST, including clinicopathologic, immunohisto-
chemical, andmolecular genetic characteristics and correspond-
ing prognosis. According to the new 7th Union for International
Cancer Control/American Joint Committee on Cancer (UICC/
AJCC) tumor-node-metastasis (TNM) system, progression rates
of gastric GIST were 0% to 3.6% in stage I, 12% to 316% in
stage II, 55% in stage IIIA, and 86% in stage IIIB.10 Gastric
GIST had a more favorable prognosis than other GISTs.11
There have been a number of studies on clinical outcome,
risk of recurrence, prognosis, and imatinib therapy for all GISTs
including gastric GIST. However, there has been no multicenter
study on gastric GIST patients with long-term follow-up that has
sufficient information regarding follow-up and surgery. The aim
of this studywas to evaluate the treatment andprognosis of gastric
GISTs according to the 7th UICC/AJCC TNM system and the
modified National Institutes of Health (NIH) risk classification.
MATERIALS AND METHODS
Study Cohort and Data Collection
The study cohort consisted of 1057 patients with gastric
GISTwho were treated with surgery between January 2000 and
December 2007 at 1 of 13 institutions in Korea: Ulsan Univer-
sity, Seoul National University, Sungkyunkwan University,
Yonsei University, Keimyung University, Dong-A University,
National Cancer Center, Ajou University, Seoul National Uni-
versity Bundang Hospital, the Catholic University Yeouido St.
Mary’s Hospital, Chungnam University, Soonchunhayng Uni-
versity, and the Catholic University Incheon St. Mary’s Hospital
and 2 institutions in Japan: Osaka University and Kanagawa
Cancer Center Hospital. The diagnosis of GIST was confirmed
at each institution by positive staining for KIT (CD117) protein
and/or CD34 as assessed by immunohistochemical staining,
regardless of myogenic and neurogenic markers.
Data were collected by reviewing the medical records and
prospectively designed gastric GIST database from each institu-
tion. The Institutional Review Board of each participating
institution approved this study. All data were collected in the
same case report form (CRF) from each institution, and data
were collected without revealing any personal information.
Personal Characteristics and Follow-Up
Clinicopathologic characteristics included age, gender,
weight (kg), height (m), preoperative metastatic status, preo-
perative symptoms, tumor location, tumor size (cm), mitotic
count (/50 high power field [HPF]), National Institutes of Health
(NIH) classification, and whether the patient received pre- or
postoperative imatinib mesylate treatment. Surgical outcomes
included operation date, operation method, radicality, type of
surgery, intraoperative tumor rupture, combined surgery, oper-
ation time (minute), postoperative hospital stay (day), compli-
cations, and death within 30 days after operation. Fifty-one
patients who could not be classified via NIH classification, 10
patients lost to follow-up, and 30 preoperative M1 patients were
Kim et alexcluded in the analysis of recurrence and long-term survival.
The follow-up schedule for patients after curative resection
in most institutions was as follows: physical examination,
2 | www.md-journal.comendoscopy, and abdominal pelvic computed tomography
(CT) scan performed annually for very low-risk or low-risk
patients and every 6 months for intermediate or high-risk
patients. Recurrence was diagnosed from clinical, radiologic,
or endoscopic findings of disease.
Statistics
For statistical analysis, qualitative data are presented as
number (%). Continuous variables are expressed as mean with
standard deviation (SD). Actuarial recurrence free survival was
calculated using the Kaplan–Meier method. Factors associated
with recurrence were tested by univariate log-rank analysis.
Variables that were significant in univariate analysis were
entered into multivariate analysis. Multivariate analysis was
performed with the Cox proportional hazard regression model.
Odds ratio (OR) for comparison of the 2 groups was summar-
ized with its 95% confidence interval (CI) and P-value using
logistic regression. ORs were also adjusted for factors affecting
the response variable. All statistical analyses were carried out
using PASW ver. 18.0 (IBM Co., Armonk, NY); the level of
significance was set at P< 0.05.
RESULTS
Annual Patient Number
The number of patients with gastric GIST increased
annually. Laparoscopic surgery was performed in more than
half of the patients at 2006 (Figure 1).
Clinicopathologic Characteristics of 1057 Gastric
GISTs
The mean age of the patients was 58.6 years, and there
were approximately the same number of male and female
patients. Thirty patients (2.8%) had distant metastasis preopera-
tively. There were 11 cases of metastasis to the liver, 19 to the
peritoneum, 2 to the pancreas, 1 to the spleen, and 1 to the lungs
and bone. Almost half of the patients had symptoms such as
abdominal pain (36.4%), dyspepsia (30.2%), melena (18.5%),
and a palpable mass (4.4%). Other symptoms were fatigue,
diarrhea, dizziness, dyspnea, shoulder pain, and chest pain. The
with gastric GIST increased annually. Laparoscopic surgery was
performed in more than half of the patients since 2006.most common site was the upper body (41.7%) of the stomach.
The most common category of tumor size was >2.1 cm and
5 cm (51.8%). The median tumor size was 4.0 cm. Only 9
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Clinicopathologic Characteristics of 1057 Gastric
GISTs
n¼ 1057 (%)
Age (years) 58.6 11.8
Gender
Male 531 (50.2)
Female 526 (49.8)
BMI (kg/m2) 24.0 3.1
Preoperative metastasis
No 1027 (97.2)
Yes 30 (2.8)
Symptom
Asymptomatic 502 (47.5)
Symptomatic

555 (52.5)
Abdominal pain 222 (36.4)
Dyspepsia 184 (30.2)
Melena 113 (18.5)
Palpable mass 27 (4.4)
Weight loss 20 (3.3)
Others 44 (7.2)
Tumor location
Cardia 145 (13.7)
Upper 1/3 441 (41.7)
Middle 1/3 192 (18.2)
Lower 1/3 239 (22.6)
Mixed 18 (1.7)
Undefined 22 (2.1)
Tumor size (cm)
2 131 (12.4)
>2.1 to 5 548 (51.8)
>5.1 to 10 239 (22.6)
>10.1 139 (13.2)
Median tumor size (cm, range) 4.0 (0.2–33)
Imatinib mesylate treatment
Preoperative 9 (0.9)
Postoperative 94 (8.9)
Both 5 (0.5)
BMI¼ body mass index
Combined number.
TABLE 2. Surgical Outcomes of 1057 Gastric GIST
n¼ 1057 (%)
Operative method
Laparoscopic surgery 399 (37.7)
Open surgery 638 (60.4)
Conversion to open surgery 19 (1.8)
No resection 1 (0.1)
Radicality
R0 1018 (96.3)
R1 18 (1.7)
R2 20 (1.9)
No resection 1 (0.1)
Type of surgery
Wedge resection 793 (75.0)
Partial gastrectomy 134 (12.7)
Total gastrectomy 105 (9.9)
Enucleation 19 (1.8)
Others 6 (0.6)
Intraoperative tumor rupture
Yes 17 (1.6)
No 1040 (98.4)
Combined surgery (other organ)
No 868 (82.1)
Yes 189 (17.9)
Operation time (minute) 126.4 78.5
Postoperative hospital stay (days) 9.1 7.3
Postoperative complication

No 971 (91.9)
Yes 86 (8.1)
Wound infection 22
Ileus 12
Bleeding, intraabdominal 11
Bleeding, intraluminal 6
Narrowing 5
Leakage 5
Others 34
Postoperative mortality 2 (0.2)

Combined number.
Medicine  Volume 94, Number 41, October 2015 Long-Term Surgical Outcome of 1057 Gastric GISTspatients (0.9%) were treated by imatinib preoperatively and 94
(8.9%) postoperatively (Table 1).
Surgical Outcomes of 1057 Gastric GISTs
Complete resection (R0 resection) was achieved in 1018
patients (96.3%). Laparoscopic surgery was performed in 399
patients (37.7%), even though more than half the patients
underwent open surgery. Various types of surgery were per-
formed and included wedge resection for 793 patients (75.0%),
partial gastrectomy for 134 patients (12.7%), total gastrectomy
for 105 patients (9.9%), and enucleation for 19 patients (1.8%).
Intraoperative tumor rupture occurred in only 17 patients
(1.6%). Postoperative complications occurred in 86 (8.1%)
patients. Wound infection was found in 22 patients, ileus in
12 patients, intraabdominal bleeding in 11 patients, and intra-
luminal bleeding in 6 patients. Two patients (0.2%) died within
30 days after surgery (Table 2).
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.Modified NIH Risk Classification According to
Tumor Size
The most common NIH risk was low-risk (38.4%), even
though there were 138 (13.7%) patients with tumor >10 cm. In
clinical practice, the decision to perform surgery for gastric
GIST depends on preoperative tumor size. The percentage of
patients who were classified as high-risk gastric GIST stratified
by tumor size were 1.8% in 2 cm, 12.2% in >2.1 cm and
5 cm, 39.0% in >5.1 cm and 10 cm, and 100% in >10.1 cm
(Table 3).
Five-Year Recurrence-Free Survival Rates by
Modified NIH Risk Classification and 7th UICC/
AJCC TNM System
According to the NIH classification, the 5-year recurrence-
free survival rates were 9% to 99% in very low- or low-risk
patients, 96.3% in intermediate-risk, and 74.9% in high-risk
patients. Moreover, according to the 7th UICC/AJCC TNM
www.md-journal.com | 3
TABLE 3. Modified NIH Risk Classification According to
Tumor Size (n¼1006)
Very Low Low Intermediate High
2 cm 96 0 16 2 114
>2.1 cm to 5 cm 4 385 70 64 523
>5.1 cm to 10 cm 0 1 140 90 231
>10.1 cm 0 0 0 138 138
Kim et alsystem, the 5-year recurrence-free survival rates were 95% to
99% in stage I, 94.1% in stage II, 74.1% in stage IIIA, 48.6% in
stage IIIB, and 50.0% in stage IV patients (Figure 2).
On survival analysis of high-risk patients according to
TNM system, the 5-year recurrence-free survival rates were
91.6% in stage II, 74.1% in stage IIIA, and 48.6% in stage IIIB
patients (Figure 3).
Recurrence
Among 1057 patients, 51 patients who could not be
classified using the NIH classification, 10 patients lost to
follow-up, and 30 preoperative M1 patients were excluded.
The median follow-up duration of 967 patients was 95.2 (0.1–
167.9) months. The overall recurrence rate was 8.9%. One
hundred three episodes of recurrence occurred in 86 patients:
45 in the liver, 28 in the peritoneum, 3 in the bone, 1 in the
axilla, and 4 in undefined sites. In addition, there were 23
incidences of local recurrence; 18 occurred in previous oper-
ation sites, 3 in other sites of the stomach, and 1 in the distal
esophagus. Most recurrences occurred in patients who were
intermediate- or high risk (Table 4).
Factors Associated With Recurrence Following
100 386 226 294Surgical Treatment for Gastric GIST
On univariate analysis, gender, age, preoperative symp-
tom, tumor location, tumor size, tumor rupture during surgery,
FIGURE 2. Five-year recurrence-free survival rate by modified NIH risk
NIH classification, the 5-year recurrence-free survival rates were 98% to
and 74.9% in high-risk patients. Moreover, according to the 7th UICC
95% to 99% in stage I patients, 94.1% in stage II, 74.1% in stage III
4 | www.md-journal.commitotic count, operation method, postoperative complication,
and radicality were associated with recurrence. In contrast,
independent factors associated with recurrence following sur-
gical treatment on multivariate analysis for gastric GIST were
gender (odds radio [OR] 0.48, 0.27< 95% confidence interval
[CI]< 0.85, P¼ 0.012), tumor size (OR 3.85, 1.77< 95%
CI< 3.66, P< 0.001), mitotic count (OR 13.93, 4.73< 95%
CI< 16.80, P< 0.001), and radicality (OR 5.55, 1.17< 95%
CI< 13.46, P¼ 0.027) (Table 5).
DISCUSSION
This large-scale multicenter and retrospective study can be
useful for evaluating clinical outcomes of gastric GIST, which
is a rare disease. Previous studies using a national registry
database had some limitations,9,12 such as a lack of sufficient
information regarding surgery and follow-up visits. This infor-
mation can affect the surgical outcome of patients with gastric
GIST, because the gold standard for localized primary gastric
GIST is surgical resection. Moreover, although the risk of
recurrence of all GISTs after surgery has been analyzed and
published,6 the risk of recurrence of gastric GIST should be
investigated separately, because gastric GIST has a more favor-
able prognosis than other GISTs. This study was conducted on
patients who had gastric GIST and long-term follow-up using a
prospectively designed database in 15 representative institutes
in Korea and Japan.
Compared to results in Western countries,9,11 patients in
this study were younger and their gastric GIST was detected
earlier, likely due to improved nationwide surveillance for
gastric cancer in Korea and Japan. Therefore, the patients in
this study have distinctive characteristics, such as smaller tumor
size, fewer symptoms, earlier stage of tumor, more frequent
treatment with laparoscopic surgery, higher rate of R0 resection
and local resection (wedge resection or enucleation), and lower
postoperative mortality rate. These differences can explain the
difference in prognosis of gastric GIST between patients from
western and eastern countries. In this study, only 9 and 94
Medicine  Volume 94, Number 41, October 2015patients were treated with imatinib mesylate preoperatively and
postoperatively, respectively. At that time, the use of imatinib
mesylate was limited due to national insurance in Korea.
classification and 7th UICC/AJCC TNM system. According to the
99% in very low- or low-risk patients, 96.3% in intermediate-risk,
/AJCC TNM system, the 5-year recurrence-free survival rates were
A, and 48.6% in stage IIIB patients.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
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Medicine  Volume 94, Number 41, October 2015 Long-Term Surgical Outcome of 1057 Gastric GISTsIt is well known that gastric GIST usually presents in
clinical practice as gastric submucosal tumor (SMT). Almost
half of gastric SMT is found to be gastric GIST after surgery.13
As demonstrated in Table 3, preoperative tumor size can predict
the incidence of the level of risk of gastric GIST after surgery if
the tumor is GIST and thus determine the follow-up plan.
Roughly one-third of patients with gastric GIST >5.1 cm to
10 cm can be high risk.
One hundred three recurrences in 86 patients occurred, and
the most common recurrence site was the liver (43.7%). The 5-
FIGURE 3. Five-year recurrence-free survival rate of high-risk pat
recurrence-free survival rates were 91.6% in stage II, 74.1% in stayear recurrence-free survival rate of very low-, low-, and
intermediate-risk patients was above 96%, and the 5-year
recurrence-free survival rate of stage I and II patients using
TABLE 4. Recurrence in 967 Patients
n¼ 967 (%)
Median FU duration (month, range) 95.2 (0.1–167.9)
Recurrences
No 881 (91.1)
Yes 86 (8.9)
NIH classification
Very low 1 (1.2)
Low 4 (4.7)
Intermediate 9 (10.5)
High 72 (83.7)
Pattern (n¼ 86)
Liver 45
Peritoneum 28
Bone 3
Axilla 1
Local recurrence 23
Stomach
Operation site 18
New lesion 3
Distal esophagus 1
Others 4
NIH¼National Institutes of Health.
Combined number.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.the 7th UICC/AJCC TNM system was above 94%. Otherwise,
patients who were high risk or stage III had high recurrence
rates. High-risk patients can be divided into stage II or IIIA or
IIIB according to the TNM staging system. The 5-year recur-
rence-free survival rate of those stages of high-risk patients was
similar to the TNM stages in all risk patients. The 7th UICC/
AJCC TNM system is more reflective of the 5-year recurrence-
free survival of patients with gastric GIST rather than the
modified NIH risk classification. Therefore, adjuvant treatment
with imatinib after surgery may be reasonable for over stage
IIIA patients rather than all high-risk patients.
Tumor rupture is thought to be associated with a substan-
tially higher risk. Hohenberger et al14 stated that patients with a
preoperative spontaneous or intraoperative rupture of GIST into
the peritoneal cavity have a risk of recurrence of nearly 100%.
However, whether or not rupture is an independent risk factor
for recurrence is controversial,6 because there has been no study
on intraoperative tumor rupture and long-term prognosis.
Tumor rupture during surgery in this study occurred in 17
patients. After surgery, 5 patients had recurrence.
In other studies on all GISTs,5,6 independence adverse
prognostic factors were larger tumor, high mitotic count, non-
gastric location, presence of rupture, and male sex. The mitotic
count was a predictor of outcome following surgical resection of
112 gastric GISTs.15 On multivariate analysis of this study,
male, larger tumor, high mitotic count, and R1 or R2 resection
were associated with recurrence after curative resection of
gastric GIST. Operation method (laparoscopy vs. open) was
not a factor associated with recurrence. Further comparison
study of laparoscopy versus open surgery for gastric GIST
according to tumor size is being prepared using our data.
This study has 2 limitations. First, there is lack of central
review of pathology results from multicenter data. Pathologic
diagnosis for GIST has been well established at each institution
in Korea since 2000. Therefore, we enrolled the patients
diagnosed with gastric GIST at each institution since 2000.
Second, no molecular genetic study was performed. The method
and response of imatinib treatment has been shown to be related
to these findings. Recently, many studies of imatinib mesylate
given in accordance with IHC and molecular genetic results
ts according to NIH classification and TNM systems. The 5-year
IIIA, and 48.6% in stage IIIB patients.have been published.16–18 However, we focused on only long-
term surgical outcomes of gastric GIST regardless of molecular
genetic results.
www.md-journal.com | 5
TABLE 5. Factors Associated With Recurrence Following Surgical Treatment for Gastric GIST (n¼967)
Univariate Analysis Multivariate Analysis
Variable OR 95% CI P-Value OR 95% CI P-Value
Gender
Male/female 0.48 0.30–0.76 0.002 0.48 0.27–0.85 0.011
Age (years)
<60/60 1.72 1.08–2.74 0.023 1.32 0.76–2.32 0.327
Symptom
No/yes 3.34 2.01–5.55 <0.001 1.42 0.77–2.61 0.264
Tumor location
Cardia/upper/middle/lower/undefined 0.78 0.63–0.97 0.023 0.90 0.70–1.17 0.446
Tumor size
<2 cm/2.1 cm to 5 cm/>5.1 cm 3.85 2.89–5.13 <0.001 2.54 1.77–3.66 <0.001
Tumor rupture during surgery
No/yes 6.74 2.15–21.07 0.001 2.23 0.42–11.79 0.346
Mitotic count
5/>5 13.93 7.70–25.20 <0.001 8.91 4.73–16.80 <0.001
Operation method
Laparoscopy/open 4.57 2.45–8.53 <0.001 1.44 0.68–3.05 0.341
Complication
No/yes 3.43 1.90–6.21 <0.001 1.63 0.74–3.57 0.227
Radicality
R0/R1 or R2 5.55 2.30–13.37 <0.001 3.97 1.17–13.46 0.027
CI¼ confidence interval, OR¼ odds radio.
Kim et al Medicine  Volume 94, Number 41, October 2015CONCLUSIONS
The treatment outcome and prognosis of gastric GIST in
Korea and Japan seem more favorable compared to those in
Western countries, likely due to the greater proportion of
patients in Korea and Japan who are younger and diagnosed
at an early stage as well as the high rate of complete resection.
Compared to the modified NIH risk classification, the 7th
UICC/AJCC TNM system is more reflective of the 5-year
recurrence-free survival of patients with gastric GIST.
REFERENCES
1. Kindblom LG, Remotti HE, Aldenborg F, et al. Gastrointestinal
pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors
show phenotypic characteristics of the interstitial cells of Cajal. Am
J Pathol. 1998;152:1259–1269.
2. Hirota S, Isozaki K, Moriyama Y, et al. Gain-or-function mutations
of c-kit in human gastrointestinal stromal tumors. Science.
1998;279:577–580.
3. Tran T, Davila JA, El-Serag HB. The epidemiology of malignant
gastrointestinal stromal tumors: an analysis of 1,458 cases
from 1992 to 2000. Am J Gastroenterol. 2005;100:162–
168.
4. Bennett JJ, Rubino MS. Gastrointestinal stromal tumors of the
stomach. Surg Oncol Clin N Am. 2012;21:21–33.
5. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointest-
inal stromal tumors: recurrence patterns and prognostic factors for
survival. Ann Surg. 2000;231:51–58.6. Joensuu H, Vehtari A, Riihima¨ki J, et al. Risk of recurrence of
gastrointestinal stromal tumour after surgery: an analysis of pooled
population-based cohorts. Lancet Oncol.
2012;13:265–274.
6 | www.md-journal.com7. Joensuu H, Eriksson M, Hatrmann J, et al. Twelve vs 36 months of
adjuvant imatinib (IM) as treatment of operable GIST with a high
risk of recurrence: final results of a randomized trial (SSGXVIII/
AIO). 47th Annual Meeting of the American Society of Clinical
Oncology. Abstract No. LBA1. Chicago (IL), June 5, 2011.
8. Raut CP, Posner M, Desai J, et al. Surgical management of advanced
gastrointestinal stromal tumors after treatment with targeted systemic
therapy using kinase inhibitors. J Clin Oncol. 2006;24:2325–2331.
9. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of
the stomach: a clinicopathologic, immunohistochemical, and molecu-
lar genetic study of 1765 cases with long-term follow-up. Am J Surg
Pathol. 2005;29:52–68.
10. Agaimy A. Gastrointestinal stromal tumors (GIST) from risk
stratification systems to the new TNM proposal: more questions than
answers? A review emphasizing the need for a standardized GIST
reporting. Int J Clin Exp Pathol. 2010;3:461–471.
11. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on
morphology, molecular pathology, prognosis, and differential diag-
nosis. Arch Pathol Lab Med. 2006;130:1466–1478.
12. Woodall CE III, Brock GN, Fan J, et al. An evaluation of 2537
gastrointestinal stromal tumors for a proposed clinical staging
system. Arch Surg. 2009;144:670–678.
13. Yang HK, Kim MC, Kim YW, et al. Nationwide survey of
laparoscopic gastric surgery in Korea. J Korean Gastric Cancer
Assoc. 2004;4:196–204.
14. Hohenberger P, Ronellenfitsch U, Oladeji O, et al. Pattern of
recurrence in patients with ruptured primary gastrointestinal stromal
tumour. Br J Surg. 2010;97:1854–1859.15. Yang HK, Park do J, Lee HJ, et al. Clinicopathologic characteristics
of gastrointestinal stromal tumor of the stomach. Hepatogastroenter-
ology. 2008;55:1925–1930.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
phenotype: a diagnostic pitfall: morphologic and molecular16. Zheng S, Huang KE, Pan YL, et al. KIT and BRAF heterogeneous
mutations in gastrointestinal stromal tumors after secondary imatinib
resistance. Gastric Cancer. 2015;18:796–802.
Medicine  Volume 94, Number 41, October 201517. Tap WD, Schwartz GK. That’s the ‘‘GIST’’ of it: use of adjuvant
imatinib after resection of a primary GI stromal tumor. J Clin Oncol.
2014;32:1543–1546.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.18. Antonescu CR, Romeo S, Zhang L, et al. Dedifferentiation in
gastrointestinal stromal tumor to an anaplastic KIT-negative
Long-Term Surgical Outcome of 1057 Gastric GISTscharacterization of 8 cases occurring either de novo or afterimatinib therapy. Am J Surg Pathol. 2013;37:385–
392.
www.md-journal.com | 7
